About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group is interested in dissecting new cellular signaling pathways that control cancer cell proliferation and differentiation. We collaborate with academics and Biopharma Companies to perform preclinical development of new anticancer drugs. Specifically, we are interested in deciphering the role of the new MAP kinase ERK5 in cancer proliferation and survival. We are also interested in the modulation of autophagy and endoplasmic reticulum (ER) stress as new strategies to tackle cancer, to improve chemotherapy and immunotherapy treatments.
We are involved in potentiating translational aspects of our resources. We actively collaborate with Ability Pharmaceuticals SL in the preclinical/clinical development of the new antitumor drug ABTL0812, which it is Clinical Trial Phase II to treat cancer patients with advanced endometrial and squamous NSCLC cancers (NCT02201823). We uncovered the mechanism involved in the antitumor action of ABTL0812: by modulating the Akt/mTORC1 axis and ER stress, this molecule induces cancer cell death by activating cytotoxic autophagy in cancer cells.
IP: Lucas Moreno Martín-Retortillo Collaborators: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, Maria Luz Uría Oficialdegui, Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders, Raquel Hladun Alvaro, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Júlia Sansa Girona, Gabriela Guillén Burrieza, Laura Alonso Garcia, Victoria Gutierrez Valle, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Elena Andretta, Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders, Amira Idrizovic Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 60000 Reference: 2021 SGR 00638 Duration: 01/01/2022 - 30/06/2025
PMID: 39983444 Journal: LUNG CANCER Year: 2025 Reference: Lung Cancer. 2025 Feb 7;201:108105. doi: 10.1016/j.lungcan.2025.108105. Impact factor: Publication type: Paper in international publication Authors: Alfon, Jose; Bosch-Barrera, Joaquim; Cortal, Marc; Domenech, Carles; Estevez-Garcia, Purificacion; Fierro-Duran, Gemma; Gascon, Pere; Lizcano, Jose M; Martin-Martorell, Paloma; Moran, Teresa et al. DOI: 10.1016/j.lungcan.2025.108105
PMID: 38581035 Journal: Experimental Hematology & Oncology Year: 2024 Reference: Exp Hematol Oncol. 2024 Apr 5;13(1):38. doi: 10.1186/s40164-024-00503-9. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Cabre-Fernandez, Paula; Gallego, Soledad; Gallo-Oller, Gabriel; Garcia-Gilabert, Lia; Guillen Burrieza, Gabriela; Lizcano, Jose M; Moreno, Lucas; Navarro, Natalia; Pons, Guillem; Roma, Josep et al. DOI: 10.1186/s40164-024-00503-9
PMID: 39039449 Journal: BMC CANCER Year: 2024 Reference: BMC Cancer. 2024 Jul 22;24(1):876. doi: 10.1186/s12885-024-12501-5. Impact factor: Publication type: Paper in international publication Authors: Alfon, Jose; Barretina-Ginesta, Pilar; Bosch-Barrera, Joaquim; Cortal, Marc; Domenech, Carles; Estevez-Garcia, Purificacion; Fierro-Duran, Gemma; Garralda, Elena; Gascon, Pere; Gil-Martin, Marta et al. DOI: 10.1186/s12885-024-12501-5
PMID: 39075404 Journal: BMC CANCER Year: 2024 Reference: BMC Cancer. 2024 Jul 29;24(1):911. doi: 10.1186/s12885-024-12700-0. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Alfon, Jose; Barretina-Ginesta, Pilar; Bosch-Barrera, Joaquim; Cortal, Marc; Domenech, Carles; Estevez-Garcia, Purificacion; Fierro-Duran, Gemma; Garralda, Elena; Gascon, Pere; Gil-Martin, Marta et al. DOI: 10.1186/s12885-024-12700-0
PMID: 39658520 Journal: Clinical and Translational Medicine Year: 2024 Reference: Clin Transl Med. 2024 Dec;14(12):e70125. doi: 10.1002/ctm2.70125. Impact factor: Publication type: Paper in international publication Authors: Comabella, Manuel; Duarri, Anna; Eixarch, Herena; Lizcano, Jose M; Lopez Comellas, Gloria; Malhotra, Sunny; Matute-Blanch, Clara; Montalban, Xavier; Pinteac, Rucsanda; Soriano, Jordi et al. DOI: 10.1002/ctm2.70125
PMID: 37919293 Journal: Cell Death & Disease Year: 2023 Reference: Cell Death Dis. 2023 Nov 2;14(11):715. doi: 10.1038/s41419-023-06229-6. Impact factor: Publication type: Paper in international publication Authors: Alari-Pahissa, Elisenda; Artigas, Antoni; Blot, Pierre-Louis; Bolinaga-Ayala, Idoia; Cartailler, Jerome; Chousterman, Benjamin G; Colas, Eva; Denizli, Melek; Espinosa-Gil, Sergio; Faundez-Vidiella, Claudia et al. DOI: 10.1038/s41419-023-06229-6
PMID: 37926340 Journal: REVISTA ESPANOLA DE CARDIOLOGIA Year: 2023 Reference: Rev Esp Cardiol (Engl Ed). 2023 Nov 3:S1885-5857(23)00284-0. doi: 10.1016/j.rec.2023.11.001. Impact factor: Publication type: Paper in international publication Authors: Alari-Pahissa, Elisenda; Almenar-Bonet, Luis; Atienza, Felipe; Aurelio Sarralde-Aguayo, Jose; Baguda, Javier De Juan; Barge-Caballero, Eduardo; Blasco-Peiro, Teresa; Bolinaga-Ayala, Idoia; Camino, Manuela; Carlos Sanchez-Salado, Jose et al. DOI: 10.1016/j.rec.2023.11.001
PMID: 36123565 Journal: CELLULAR AND MOLECULAR LIFE SCIENCES Year: 2022 Reference: Cell Mol Life Sci. 2022 Sep 19;79(10):524. doi: 10.1007/s00018-022-04541-6. Impact factor: Publication type: Paper in international publication Authors: Bayascas, Jose R; Bolinaga-Ayala, Idoia; Colas, Eva; Dieguez-Martinez, Nora; Dolcet, Xavier; Domingo-Orti, Ines; Espinosa-Gil, Sergio; Gorgisen, Gokhan; Lizcano, Jose M; Megias-Roda, Elisabet et al. DOI: 10.1007/s00018-022-04541-6
PMID: 35806262 Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Year: 2022 Reference: Int J Mol Sci. 2022 Jun 29;23(13). pii: ijms23137257. doi: 10.3390/ijms23137257. Impact factor: Publication type: Paper in international publication Authors: Abad, Jose Luis; Bielsa, Nuria; Casas, Josefina; Casasampere, Mireia; Delgado, Antonio; Enrich, Carlos; Fabrias, Gemma; Lizcano, Jose M et al. DOI: 10.3390/ijms23137257
PMID: 35293148 Journal: Cancer Communications Year: 2022 Reference: Cancer Commun (Lond). 2022 Jun;42(6):567-571. doi: 10.1002/cac2.12282. Epub 2022 Mar 16. Impact factor: Publication type: Letter whit IF Authors: Alfon, Jose; Domenech, Carles; Lizcano, Jose Miguel; Megias-Roda, Elisabet; Munoz-Guardiola, Pau; Perez-Montoyo, Hector; Polonio-Alcala, Emma; Puig, Teresa; Ruiz-Martinez, Santiago; Sole-Sanchez, Sonia et al. DOI: 10.1002/cac2.12282
PMID: 35806262 Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Year: 2022 Reference: Int J Mol Sci. 2022 Jun 29;23(13). pii: ijms23137257. doi: 10.3390/ijms23137257. Impact factor: 5.924 Publication type: Paper in international publication Authors: Bielsa, Nuria; Casasampere, Mireia; Abad, Jose Luis; Enrich, Carlos; Delgado, Antonio; Fabrias, Gemma; Lizcano, Jose M; Casas, Josefina et al. DOI: 10.3390/ijms23137257
PMID: 34440243 Journal: Biomedicines Year: 2021 Reference: Biomedicines. 2021 Aug 18;9(8). pii: biomedicines9081039. doi: 10.3390/biomedicines9081039. Impact factor: Publication type: Paper in international publication Authors: Apostolova, Nadezda; Banuls, Celia; Bosch, Assumpcio; Casas, Caty; Fores, Joaquim; Herrando-Grabulosa, Mireia; Leiva-Rodriguez, Tatiana; Lizcano, Jose Miguel; Munoz-Guardiola, Pau; Petegnief, Valerie et al. DOI: 10.3390/biomedicines9081039
PMID: 34780645 Journal: BIOCHEMICAL JOURNAL Year: 2021 Reference: Biochem J. 2021 Dec 10;478(23):4119-4136. doi: 10.1042/BCJ20210646. Impact factor: Publication type: Paper in international publication Authors: Brown, Helen A; Dieguez-Martinez, Nora; Fernandez-Alonso, Rosalia; Findlay, Greg M; Gourlay, Robert; Lizcano, Jose M; Mansoor, Saria; McMulkin, Liam; Peltier, Julien; Rios-Szwed, Diana et al. DOI: 10.1042/BCJ20210646
PMID: 33588149 Journal: EUROPEAN JOURNAL OF CANCER Year: 2021 Reference: Eur J Cancer. 2021 Mar;146:87-94. doi: 10.1016/j.ejca.2020.12.019. Epub 2021 Feb 12. Impact factor: Publication type: Paper in international publication Authors: Alfon, Jose; Brunet, Merce; Colom, Helena; Cortal, Marc; Domenech, Carles; Gaba, Lydia; Gascon, Pere; Gomez-Ferreria, Mariana; Lizcano, Jose Miguel; Martin, Marta Gil et al. DOI: 10.1016/j.ejca.2020.12.019
PMID: 34805151 Journal: Frontiers in Cell and Developmental Biology Year: 2021 Reference: Front Cell Dev Biol. 2021 Nov 4;9:742049. doi: 10.3389/fcell.2021.742049. eCollection 2021. Impact factor: Publication type: Paper in international publication Authors: Bolinaga-Ayala, Idoia; Dieguez-Martinez, Nora; Espinosa-Gil, Sergio; Gamez-Garcia, Andres; Lizcano, Jose M; Megias-Roda, Elisabet; Munoz-Guardiola, Pau; Yoldi, Guillermo et al. DOI: 10.3389/fcell.2021.742049
PMID: 32209980 Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Year: 2020 Reference: Int J Mol Sci. 2020 Mar 23;21(6). pii: ijms21062203. doi: 10.3390/ijms21062203. Impact factor: Publication type: Paper in international publication Authors: Dieguez-Martinez, Nora; Erazo, Tatiana; Espinosa-Gil, Sergio; Gomez, Nestor; Lizcano, Jose M et al. DOI: 10.3390/ijms21062203
PMID: 32219437 Journal: JOURNAL OF EXPERIMENTAL MEDICINE Year: 2020 Reference: J Exp Med. 2020 Jun 1;217(6). pii: 151590. doi: 10.1084/jem.20191787. Impact factor: Publication type: Paper in international publication Authors: Arruabarrena-Aristorena, Amaia; Astobiza, Ianire; Barrio, Rosa; Camacho, Laura; Caro-Maldonado, Alfredo; Carracedo, Arkaitz; Carreira, Suzanne; Cortazar, Ana R; de Bono, Johann S; Fernandez-Ruiz, Sonia et al. DOI: 10.1084/jem.20191787
PMID: 32251410 Journal: Nature Chemical Biology Year: 2020 Reference: Nat Chem Biol. 2020 Jun;16(6):635-643. doi: 10.1038/s41589-020-0506-0. Epub 2020 Apr 6. Impact factor: Publication type: Paper in international publication Authors: Aguirre, Andrew J; Corona, Cesear R; Dieguez-Martinez, Nora; Espinosa, Sergio; Ferguson, Fleur M; Gray, Nathanael S; Hahn, William C; Haigis, Kevin M; Harshbarger, Wayne; He, Shuning et al. DOI: 10.1038/s41589-020-0506-0
PMID: 31943158 Journal: INTERNATIONAL JOURNAL OF CANCER Year: 2020 Reference: Int J Cancer. 2020 Aug 15;147(4):1163-1179. doi: 10.1002/ijc.32865. Epub 2020 Feb 6. Impact factor: Publication type: Paper in international publication Authors: Alfon, Jose; Ametller, Elisabet; Bragado, Paloma; Domenech, Carles; Erazo, Tatiana; Fernandez-Nogueira, Patricia; Fuster, Gemma; Gascon, Pere; Gomez-Ferreria, Mariana; Jauregui, Patricia et al. DOI: 10.1002/ijc.32865
PhD student: Sergio Espinosa Gil Director/s: Jose Miguel Lizcano De Vega University: Universitat Autònoma de Barcelona Year: 2023
On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.
The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.
A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.
